Data and performances evaluation of the SPIDIA-DNA Pan-European External Quality Assessment: 2nd SPIDIA-DNA laboratory report. by Malentacchi, F et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 6 (2016) 980–984http://d
2352-34
(http://c
DOI
n Corr
Pieracci
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleData and performances evaluation
of the SPIDIA-DNA Pan-European External
Quality Assessment: 2nd SPIDIA-DNA
laboratory report
Francesca Malentacchi a,n, Sara Pizzamiglio b,
Hady Ibrahim-Gawel c, Mario Pazzagli a, Paolo Verderio b,
Chiara Maura Ciniselli b, Ralf Wyrich c, Stefania Gelmini a
a Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Italy
b Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
c QIAGEN GmbH, Hilden, Germanya r t i c l e i n f o
Article history:
Received 29 December 2015
Received in revised form
22 January 2016
Accepted 27 January 2016
Available online 6 February 2016x.doi.org/10.1016/j.dib.2016.01.062
09/& 2016 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author at: Department of Biom
ni, 6–50139 Florence, Italy. Tel.: +0039 055
ail address: francesca.malentacchi@gmail.coa b s t r a c t
Within the EU-SPIDIA project (www.spidia.eu), the quality para-
meters of blood genomic DNA were defined [SPIDIA-DNA: an
External Quality Assessment for the pre-analytical phase of blood
samples used for DNA-based analyses – [1]; Influence of pre-
analytical procedures on genomic DNA integrity in blood samples:
the SPIDIA experience – [2]; Combining qualitative and quantita-
tive imaging evaluation for the assessment of genomic DNA
integrity: the SPIDIA experience – [3]. DNA quality parameters
were used to evaluate the laboratory performance within an
External Quality Assessment (EQA) [Second SPIDIA-DNA External
Quality Assessment (EQA): Influence of pre-analytical phase of
blood samples on genomic DNA quality – [4]. These parameters
included DNA purity and yield by UV spectrophotometric mea-
surements, the presence of PCR interferences by Kineret software
and genomic DNA integrity analysis by Pulsed Field Gel Electro-
phoresis.vier Inc. This is an open access article under the CC BY license
/j.cca.2015.12.032
edical, Experimental and Clinical Sciences, University of Florence, Viale G.
2758251; fax: +0039 055 2758261.
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F. Malentacchi et al. / Data in Brief 6 (2016) 980–984 981Here we present the specific laboratory report of the 2nd
SPIDIA-DNA EQA as an example of data and performances eva-
luation.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specification tableubject area Molecular Biology
ore specific sub-
ject areaExternal Quality Assessment for quality of genomic DNA from blood sampleype of data Table, text file, graph, figure
ow data was
acquiredSpectrophotometer (Nanodrop 1000 UV, Nanodrop), qPCR analysis (TaqMan
RNaseP detection reagents, 7900HT Fast Real-Time PCR system, Applied
Biosystems), Pulsed Field Gel Electrophoresis (CHEF DRII system, BioRad),
Kineret software (Kineret Version 1.0.5, http://www.labonnet.com)ata format Analyzed
xperimental
factorsThe participants to the 2nd SPIDIA-DNA EQA received the same blood
sample at 4 °C. After the genomic DNA (gDNA) isolation by their own pro-
cedure (within 3 days after sample arrival, storing blood at 4 °C), they sent
back the extracted DNA at 4 °C at SPIDIA facility.xperimental
featuresThe defined DNA quality parameters (DNA purity and yield, presence of
qPCR interferences and gDNA integrity) were evaluated according to an ad
hoc statistical procedure by SPIDIA facility. A dedicated report was produced
for each participant in which the performance related to each quality
parameter was reported.ata source
locationUniversity of Florence, Florence, Italy. Qiagen, Hilden, Germany. Labonnet
Ltd. Company, Jordan Valley, Israel.ata accessibility Data is with this article.D
Value of the data
 Identification of quality parameters for the evaluation of genomic DNA from blood.
 Analysis of the results of Pan European External Quality Assessment (EQA).
 Setting of a Report for the evaluation of laboratory performance for an External Quality
Assessment.1. Data
In order to inform the SPIDIA-DNA EQA participants on the quality of the extracted DNA from
blood a dedicated report was realized [1,4]. The report contains the evaluation of the performance of
the specific laboratory and the overall distribution of the participants’ data for each gDNA quality
parameter.2. Experimental design, materials and methods
Briefly, 1.2 ml of blood from a single healthy donor was sent to 174 laboratories from 26 different
European countries (Fig. 1). The participants extracted gDNA following their own procedure within
Fig. 1. Distribution of the participating laboratories to the 2nd SPIDIA DNA EQA through Europe.
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sample at 4 °C. At SPIDIA facility, the defined DNA quality parameters (DNA purity and yield, gDNA
integrity and of qPCR interferences) were evaluated and the performance of each laboratory was
defined. A specific report (Appendix A, Supplementary material) was realized to give to the partici-
pants: (I) their own performance evaluation for each gDNA quality parameter; (II) the overall per-
formance evaluation of the whole exercise and (III) the overall data distribution for each parameter.2.1. gDNA purity and quantity evaluation
At SPIDIA facility, the absorbance was measured at 260 nm, 280 nm and 320 nm wavelengths by
NanoDrop 1000 UV spectrophotometer (NanoDrop Technologies) [1,4]. DNA purity (DNAb Spidia,
Appendix A, Section A.3, right panel) was evaluated using 260 nm/280 nm ratio.
The DNA Quantity (DNAb Spidia, Appendix A, Section A.4, right panel) was evaluated as
Q (ng/ml blood)¼[(260 nm)50dilution factor elution volume]/extracted blood volume.
The specific laboratory DNA Purity (DNAb Lab, Appendix A, Section A.3, left panel) derived from
the declaration in the Result Form.
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puted by using the concentration (C), the extraction and elution volumes reported by the participants
according to the following formula:
Q (ng/ml blood)¼(C elution volume)/extracted blood volume.
The performance of each laboratory in terms of DNA purity and quantity was evaluated by
resorting to the two-step statistical procedure previously adopted [1,4]. Briefly, we computed specific
bootstrap centiles from the outlier-free distribution of DNA purity and yield derived from SPIDIA and
laboratory data. Regarding DNA purity, the 2.5th and the 97.5th bootstrap centile were used to
identify the lower and upper Action Limit (AL, blue lines) and the 10th and 90th bootstrap centile to
identify the lower and the upper Warning Limit (WL, gray lines). For DNA quantity, we used the 5th
and the 20th bootstrap centile to identify the one sided AL (blue line) and WL (gray line), respectively.
According to these limits, the performance of each participant was classified as follows:
 Out of control: if the value exceeded the upper or the lower AL or if the value was below the one
sided AL.
 Warning: if the value was between the upper AL and WL or between the lower AL and WL, or
between the one sided WL and AL.
 In control: if the value was between the lower and the upper WL, or exceeded the one sided WL
(Appendix A, Section A).
2.2. gDNA integrity
The gDNA integrity was analyzed by Pulsed Field Gel Electrophoresis (PFGE). 800 ng DNA were
analyzed in a 1% agarose gel (Ultra Pure Agarose, Invitrogen), 0.5 TBE buffer (45 mM Tris, 45 mM
Borate, 2.5 mM EDTA) and a CHEF DRII system (BioRad). Low Range PFG Marker (2.03–194 kb; New
England Biolabs) was used as DNA size marker. Electrophoresis was performed for 16 h at 10 °C with
6 V/cm and a switch time of 1–12 s. The gel was stained for 30 min using 0.5 mg/ml ethidium bromide
solution and destained for 1–2 h in distilled water. Documentation was performed using the EASY
Win32 system (Herolab) [1,4].
The images from PGFE were analyzed by ImageJ software and by a panel of expert. A dedicated
algorithm, as described in Ciniselli at al. [3], was applied to combine the expert by-eye evaluation
with the quantitative variables deriving from the ImageJ software. The final judgement classified the
laboratory performance in one of the following 3 categories: low, intermediate high integrity
(Appendix A, Section B).
2.3. qPCR interferences
The evaluation of qPCR interferences was made by Kineret software Version 1.0.5 (http://www.
labonnet.com) as previously described [1,4,5].
Amplification curve of each sample was used to calculate the kineret distance (KD) from a refer-
ence curve. For SPIDIA DNA EQA analysis, all sample amplification curves were used as reference
curve. The KD can be interpreted as a metric reflecting PCR interference due to unknown factors that
adversely affects the PCR [5]. qPCR was performed using 1 μl of DNA and 11.5 μl of PCR mix containing
1 TaqMan RNaseP detection reagents (Applied Biosystems) and 1 Universal PCR Master Mix
(Applied Biosystems) by 7900 HT Fast Real-Time PCR system (Applied Biosystems). Each sample was
run in triplicate.
The performance was classified as follows:
 strong outlier (presence of interferences): value exceeding the 9.21 threshold;
 weak outlier (probably presence of some interferences): value between the 5.99 and the 9.21
threshold;
 in control (no interferences): value under the 5.99 threshold.
F. Malentacchi et al. / Data in Brief 6 (2016) 980–984984The message missing appeared when it was not possible to analyze the sample with the Kineret
software (Appendix A, Section C).
2.4. Overall performance evaluation of the whole exercise
The participating laboratory performance for each quality parameter was summarized in a dedi-
cated section (Appendix A, Section D), according to the traffic light color. When performance eva-
luation was not possible, a specific explanation was reported.
The performance was visually summarized by a table and a radar graph.Acknowledgments
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